TCT 2019 | COMPLETE: Sub-Study to Find Out Complete Optimal Revascularization Timing in STEMI

Courtesy of SBHCI.

The COMPLETE study was carried out to assess the benefit of complete revascularization vs culprit vessel revascularization in the context of ST elevation acute myocardial infarction. This COMPLETE sub-study presented at TCT 2019 scientific sessions simultaneously published in JACC assessed the optimal timing of complete revascularization. The general study had already shown the latter is superior to treating only the culprit vessel. 

Highlights TCT 2019

The sub-study assessed two groups: complete revascularization done during index hospitalization (n=2702) and complete revascularization after discharge (n=1339). Patients in the first group passed through the cath lab again at mean 1 day after infarction and patients in the second group at mean 23 days. 

Outcomes at 3 years for primary end point (composite of death and repeat MI) and secondary end points such as death, MI or ischemia driven revascularization were analyzed in both groups. 

For both the primary and secondary end points, both groups undergoing complete revascularization (during index hospitalization and after discharge) saw a benefit vs. culprit vessel revascularization alone. 

There seems to be no difference between complete revascularization at hospitalization or after discharge and in both arms the major benefit was observed after 45 days of MI. With this data we could speculate that complete revascularization should follow physician criterion on a case by case basis. Given the curves start growing apart more significantly as of day 45, it seems reasonable to do it before this point. 

Courtesy of SBHCI.

Link to the SBHCI publication HERE

complete-substudy

Original Title: COMPLETE TIMING SUBSTUDY – A Randomized Trial Of Complete Staged Revascularization Vs. Infarct Artery PCI Alone In Patients With Acute Myocardial Infarction And Multivessel Disease — Importance Of Revascularization Timing.

Author of the Original Article: David A. Wood.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....